Какие факторы влияют на эффективность длительной анальгетической терапии при остеоартрите? Анализ данных многоцентрового 3-месячного исследования ПАРАЦЕЛЬС
Какие факторы влияют на эффективность длительной анальгетической терапии при остеоартрите? Анализ данных многоцентрового 3-месячного исследования ПАРАЦЕЛЬС
Каратеев А.Е., Лила А.М., Погожева Е.Ю. и др. Какие факторы влияют на эффективность длительной анальгетической терапии при остеоартрите? Анализ данных многоцентрового 3-месячного исследования ПАРАЦЕЛЬС. Терапевтический архив. 2019; 91 (5): 68–75. DOI: 10.26442/00403660.2019.05.000233
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
При лечении остеоартрита (ОА) следует учитывать факторы, которые могут влиять на эффективность терапии.
Цель исследования: определение факторов, влияющих на эффективность длительной анальгетической терапии при ОА.
Материалы и методы. В исследование включены 6448 больных (70,9% женщины и 29,1% мужчины), среднего возраста 57,8±10,2 года, с выраженной болью [≥40 мм по визуальной аналоговой шкале]. Все пациенты получали препарат неомыляемых соединений авакадо и сои (НСАС) 300 мг/сут. Для купирования боли в начале и в ходе исследования применялся препарат кетопрофен лизиновая соль (КЛС) 320 мг/сут. Критерием эффективности являлось снижение боли ≥50% и удовлетворенность лечением ≥4 по 5-балльной шкале. Оценивалось влияние ряда факторов на результат лечения.
Результаты. За 3 мес лечения боль снизилась с 63,7±12,0 до 14,2±11,7 мм. Оценили результат как «хороший» или «превосходный» 81,7% больных. Нежелательные реакции отмечались редко. Суммарно хороший ответ на терапию отмечен у 87,4% больных. Пол, индекс массы тела ≥30 кг/м2, сахарный диабет 2-го типа, плохой эффект нестероидных противовоспалительных препаратов и медленнодействующих противовоспалительных средств в анамнезе не влияли на результат. Эффект был меньше у лиц ≥65 лет [отношение шансов (ОШ) 0,418; 95% доверительный интервал (ДИ) 0,342–0,509, р<0,001], с рентгенологической стадией ≥2 по Kellgren–Lawrence (ОШ 0,556; 95% ДИ 0,298–0,738, р<0,001), с болью в покое (ОШ 0,690; 95% ДИ 0,596–0,800, р<0,001), синовитом (ОШ 0,778; 95% ДИ 0,673–0,900, p=0,001), болью в области энтезисов (ОШ 0,846; 95% ДИ 0,616–0,957, p=0,032), а также при наличии дескрипторов центральной сенситизации (ЦС; ОШ 0,530; 95% ДИ 0,458–0,613, р<0,001).
Заключение. Комбинация НСАС и КЛС позволяет добиться успешного контроля боли при ОА. Ряд факторов: возраст ≥65 лет, рентгенологическая стадия ОА ≥2, боль в покое, синовит, боль в области энтезисов и наличие дескрипторов ЦС ассоциируются с худшим результатом лечения.
Ключевые слова: остеоартрит, лечение, медленнодействующие противовоспалительные средства, неомыляемые соединения авокадо и сои, пиаскледин, нестероидные противовоспалительные препараты, кетопрофен лизиновая соль, артрозилен, факторы эффективности.
Aim to identify factors affecting the effectiveness of long-term analgesic therapy in OA.
Materials and methods. The study included 6448 patients (70.9% female and 29.1% male), middle age 57.8±10.2 years, with severe pain [≥40 mm on the visual analog scale]. All patients received the preparation of avocado-soybean unsaponifiables (ASU) 300 mg/day. For pain relief at the beginning and during the study, the drug Ketoprofen lysine salt (KLS) 320 mg/day was used. The efficiency criterion was pain reduction ≥50% and satisfaction with treatment ≥4 on a 5-point scale. The influence of a number of factors on the result of treatment was evaluated.
Results. For 3 months of treatment, the pain decreased from 63.7±12.0 to 14.2±11.7 mm VAS. The result was evaluated as "good" or "excellent" 81.7% of patients. Adverse reactions were rare. In total, a good response to therapy was noted in 87.4% of patients. Gender, body mass index ≥30 kg/m2, type 2 diabetes mellitus, poor effect of non-steroidal anti-inflammatory drugs (NSAIDs) and Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSADOA) in history did not affect the result. The effect was lower in persons >65 years [odds ratio (OR) 0.418; 95% confidence interval (CI) 0.342–0.509, p<0.001], with radiological stage >2 by Kellgren–Lawrence (OR 0.556; 95% CI 0.298–0.738, p<0.001), with pain at rest (OR 0.690; 95% CI 0.596–0.800, p<0.001), synovitis (OR 0.778; 95% CI 0.673–0.900, p=0.001), pain in the enthesis region (OR 0.846; 95% CI 0.616–0.957, p=0.032), and also in the presence of central sensitization descriptors (CS; OR 0.530; 95% CI 0.458–0.613, p<0.001).
Conclusion. The combination of ASU and NSAID (KLS) allows for successful control of pain in OA. Factors such as age >65 years, stage OA of K/L >2, pain at rest, synovitis, pain in the region of enthesis and the presence of CS descriptors associated with the worst treatment outcome.
Keywords: osteoarthritis, treatment, SYSADOA, avocado-soybean unsaponifiables, nonsteroidal anti-inflammatory drugs, ketoprofen lysine salt.
Цель исследования: определение факторов, влияющих на эффективность длительной анальгетической терапии при ОА.
Материалы и методы. В исследование включены 6448 больных (70,9% женщины и 29,1% мужчины), среднего возраста 57,8±10,2 года, с выраженной болью [≥40 мм по визуальной аналоговой шкале]. Все пациенты получали препарат неомыляемых соединений авакадо и сои (НСАС) 300 мг/сут. Для купирования боли в начале и в ходе исследования применялся препарат кетопрофен лизиновая соль (КЛС) 320 мг/сут. Критерием эффективности являлось снижение боли ≥50% и удовлетворенность лечением ≥4 по 5-балльной шкале. Оценивалось влияние ряда факторов на результат лечения.
Результаты. За 3 мес лечения боль снизилась с 63,7±12,0 до 14,2±11,7 мм. Оценили результат как «хороший» или «превосходный» 81,7% больных. Нежелательные реакции отмечались редко. Суммарно хороший ответ на терапию отмечен у 87,4% больных. Пол, индекс массы тела ≥30 кг/м2, сахарный диабет 2-го типа, плохой эффект нестероидных противовоспалительных препаратов и медленнодействующих противовоспалительных средств в анамнезе не влияли на результат. Эффект был меньше у лиц ≥65 лет [отношение шансов (ОШ) 0,418; 95% доверительный интервал (ДИ) 0,342–0,509, р<0,001], с рентгенологической стадией ≥2 по Kellgren–Lawrence (ОШ 0,556; 95% ДИ 0,298–0,738, р<0,001), с болью в покое (ОШ 0,690; 95% ДИ 0,596–0,800, р<0,001), синовитом (ОШ 0,778; 95% ДИ 0,673–0,900, p=0,001), болью в области энтезисов (ОШ 0,846; 95% ДИ 0,616–0,957, p=0,032), а также при наличии дескрипторов центральной сенситизации (ЦС; ОШ 0,530; 95% ДИ 0,458–0,613, р<0,001).
Заключение. Комбинация НСАС и КЛС позволяет добиться успешного контроля боли при ОА. Ряд факторов: возраст ≥65 лет, рентгенологическая стадия ОА ≥2, боль в покое, синовит, боль в области энтезисов и наличие дескрипторов ЦС ассоциируются с худшим результатом лечения.
Ключевые слова: остеоартрит, лечение, медленнодействующие противовоспалительные средства, неомыляемые соединения авокадо и сои, пиаскледин, нестероидные противовоспалительные препараты, кетопрофен лизиновая соль, артрозилен, факторы эффективности.
________________________________________________
Aim to identify factors affecting the effectiveness of long-term analgesic therapy in OA.
Materials and methods. The study included 6448 patients (70.9% female and 29.1% male), middle age 57.8±10.2 years, with severe pain [≥40 mm on the visual analog scale]. All patients received the preparation of avocado-soybean unsaponifiables (ASU) 300 mg/day. For pain relief at the beginning and during the study, the drug Ketoprofen lysine salt (KLS) 320 mg/day was used. The efficiency criterion was pain reduction ≥50% and satisfaction with treatment ≥4 on a 5-point scale. The influence of a number of factors on the result of treatment was evaluated.
Results. For 3 months of treatment, the pain decreased from 63.7±12.0 to 14.2±11.7 mm VAS. The result was evaluated as "good" or "excellent" 81.7% of patients. Adverse reactions were rare. In total, a good response to therapy was noted in 87.4% of patients. Gender, body mass index ≥30 kg/m2, type 2 diabetes mellitus, poor effect of non-steroidal anti-inflammatory drugs (NSAIDs) and Symptomatic Slow-Acting Drugs in Osteoarthritis (SYSADOA) in history did not affect the result. The effect was lower in persons >65 years [odds ratio (OR) 0.418; 95% confidence interval (CI) 0.342–0.509, p<0.001], with radiological stage >2 by Kellgren–Lawrence (OR 0.556; 95% CI 0.298–0.738, p<0.001), with pain at rest (OR 0.690; 95% CI 0.596–0.800, p<0.001), synovitis (OR 0.778; 95% CI 0.673–0.900, p=0.001), pain in the enthesis region (OR 0.846; 95% CI 0.616–0.957, p=0.032), and also in the presence of central sensitization descriptors (CS; OR 0.530; 95% CI 0.458–0.613, p<0.001).
Conclusion. The combination of ASU and NSAID (KLS) allows for successful control of pain in OA. Factors such as age >65 years, stage OA of K/L >2, pain at rest, synovitis, pain in the region of enthesis and the presence of CS descriptors associated with the worst treatment outcome.
Keywords: osteoarthritis, treatment, SYSADOA, avocado-soybean unsaponifiables, nonsteroidal anti-inflammatory drugs, ketoprofen lysine salt.
Список литературы
1. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017:446 с. [Rossijskie klinicheskie rekomendacii. Revmatologiya. Pod red. EL. Nasonova. Moscow: GEOTAR-Media, 2017: 446 s. (In Russ.)]. ISBN 978-5-9704-4261-6
2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X Epub 2015 Aug 28
3. Балабанова Р.М., Эрдес Ш.Ф. Распространенность ревматических заболеваний в России в 2012–2013 гг. Научно-практическая ревматология. 2015;53(2):120-4 [Balabanova RM, Erdes ShF. Rasprostranennost` revmaticheskix zabolevaniĭ v Rossii v 2012–2013 gg. Nauchno-prakticheskaya revmatologiya. 2015;53(2):120-4 (In Russ.)].
4. Фоломеева O.M., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes ShF. Rasprostranennost revmaticheskix zabolevaniĭ v populyaciyax vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008;46(4):4-13 (In Russ.)].
5. "Arthritis-Related Statistics: Prevalence of Arthritis in the United States". Centers for Disease Control and Prevention, US Department of Health and Human Services. 9 November 2016. На сайте: https://www.cdc.gov/ arthritis/data_statistics/arthritis-related-stats.htm
6. Pfuntner A, Wier LM, Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011: Statistical Brief #162. Source Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006-2013 Sep.
7. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 Epub 2014 Jan 24
8. Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.20 15.11.010 Epub 2015 Dec 2
9. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136 Epub 2016 Aug 19
10. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9
11. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2): CD002946.
12. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90.
13. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117.
14. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.
15. Moore R, Moore O, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9.
16. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. 2010;62(3):172-88.
17. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989;83:21-7.
18. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):731-8. Epub 2013 May 17
19. Каратеев А.Е., Журавлева М.В., Алексеев В.В. и др. Эффективность комбинации лекарственных форм кетопрофена лизиновой соли (Артрозилен®) у пациентов с мышечно-скелетной болью в клинической практике: Исследование КУЛОН (Кетопрофен: удовлетворенность лечением и оценка нежелательных явлений). Клиническая фармакология и терапия. 2013;22(4):22-30 [Karateev AE, Zhuravleva MV, Alekseev VV i dr. Effektivnost kombinacii lekarstvenny`x form ketoprofena lizinovoĭ soli (Artrozilen®) u pacientov s myshechno-skeletnoj bolyu v klinicheskoj praktike: Issledovanie KULON (Ketoprofen: udovletvorennost lecheniem i ocenka nezhelatelnyx yavleniĭ). Klinicheskaya farmakologiya i terapiya. 2013;22(4):22-30 (In Russ.)].
20. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;(5):CD002947. doi: 10.1002/1 4651858.CD002947.pub2
21. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408.
22. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014 Feb;73(2):376-84. Epub 2013 Jan 23. doi: 10.1136/annrheumdis-2012-202485
23. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016;54(5):217-26. Epub 2016 Nov 28.
24. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1955-65. doi: 10.1016/j.joca.2015.05.016 Epub 2015 May 30.
25. Belluzzi E, El Hadi H, Granzotto M, et al. Systemic and Local Adipose Tissue in Knee Osteoarthritis. J Cell Physiol. 2017 Aug;232(8):1971-8. doi: 10.1002/jcp.25716 Epub 2017 Mar 3.
26. Nawai A, Leveille SG, Shmerling RH, et al. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017 Feb 21. doi: 10.1007/s40520-016-0700-9 [Epub ahead of print.]
27. Larsson C, Hansson EE, Sundquist K, Jakobsson U. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2016 Nov 25;1-9. doi: 10.1080/03009742.2016.1218543 [Epub ahead of print.]
28. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008 Sep 2;9:116. doi: 10.1186/1471-2474-9-116
29. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4
30. Chan WP, Huang GS, Hsu SM, et al. Radiographic joint space narrowing in osteoarthritis of the knee: relationship to meniscal tears and duration of pain. Skeletal Radiol. 2008 Oct;37(10):917-22. doi: 10.1007/s00256-008-0530-8 Epub 2008 Jul 2.
31. Murphy SL, Lyden AK, Phillips K, et al. Association between pain, radiographic severity, and centrally-mediated symptoms in women with knee osteoarthritis. Arthritis Care Res (Hoboken). 2011 Nov;63(11):1543-9. doi: 10.1002/acr.20583
32. Raman S, FitzGerald U, Murphy JM. Interplay of Inflammatory Mediators with Epigenetics and Cartilage Modifications in Osteoarthritis. Front Bioeng Biotechnol. 2018 Mar 14;6:22. doi: 10.3389/fbioe.2018.00022. eCollection 2018
33. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1825-34. doi: 10.1016/j.joca.2015.08.015
34. Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425.
35. Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One. 2018 Jan 12;13(1):e0191045. doi: 10.1371/journal.pone.01910 45.eCollection 2018
36. Snelling SJ, Bas S, Puskas GJ, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One. 2017 Apr 11;12(4):e0175109. doi:10.1371/journal.pone.0175109.eCollect ion 2017
37. Каратеев А.Е., Лила А.М., Погожева Е.Ю. и др. Эффективность мелоксикама при острой боли в спине: данные наблюдательного неинтервенционного многоцентрового исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(6):24-30 [Karateev AE, Lila AM, Pogozheva EYu, i dr. Effektivnost` meloksikama pri ostroj boli v spine: danny`e nablyudatel`nogo neintervencionnogo mnogocentrovogo issledovaniya. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2018;118(6):24-30 (In Russ.)].
38. Каратеев А.Е., Погожева Е.Ю., Филатова Е.С., и др. Результаты российского многоцентрового исследования НОТА (НПВП для Обезболивания: Терапевтический Анализ). Терапевтический архив. 2018;90(6):65-73 [Karateev AE, Pogozheva EYu, Filatova ES, i dr. Rezul`taty` rossijskogo mnogocentrovogo issledovaniya NOTA (NPVP dlya Obezbolivaniya: Terapevticheskij Analiz). Therapeutic Archive. 2018;90(6):65-73 (In Russ.)].
39. Rai MF, Brophy RH, Sandell LJ. Osteoarthritis following meniscus and ligament injury: insights from translational studies and animal models. Curr Opin Rheumatol. 2019 Jan;31(1):70-9. doi: 10.1097/BOR.0000000 000000566
40. Mattap SM, Aitken D, Wills K, et al. Patellar tendon enthesis abnormalities and their association with knee pain and structural abnormalities in older adults. Osteoarthritis Cartilage. 2019 Mar; 27(3):449-458. doi: 10.1016/j.joca.2018.11.009 [Epub 2018 Dec 5]
41. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И., Эрдес Ш.Ф., Филатова Е.Г. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-5 [Filatova ES, Turovskaya EF, Alekseeva LI, E`rdes ShF, Filatova EG. Analiz patogeneticheskix mexanizmov xronicheskoj sustavnoj boli u bolnyx revmatoidny`m artritom i osteoartrozom kolennyx sustavov. Nauchno-prakticheskaya revmatologiya. 2014;52(6):631-5 (In Russ.)]. https://doi.org/10.14412/1995-4484-2014-631-635
42. Petersen KK, Olesen AE, Simonsen O, Arendt-Nielsen L. Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis. Pain. 2018 Oct 26. doi: 10.1097/j.pain.0000000000001427 [Epub ahead of print.]
43. De Oliveira Silva D, Rathleff MS, Petersen K, et al. Manifestations of Pain Sensitization Across Different Painful Knee Disorders: A Systematic Review Including Meta-analysis and Metaregression. Pain Med. 2018 Nov 13. doi: 10.1093/pm/pny177 [Epub ahead of print.]
2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X Epub 2015 Aug 28
3. Balabanova RM, Erdes ShF. Rasprostranennost` revmaticheskix zabolevaniĭ v Rossii v 2012–2013 gg. Nauchno-prakticheskaya revmatologiya. 2015;53(2):120-4 (In Russ.).
4. Folomeeva OM, Galushko EA, Erdes ShF. Rasprostranennost revmaticheskix zabolevaniĭ v populyaciyax vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008;46(4):4-13 (In Russ.).
5. "Arthritis-Related Statistics: Prevalence of Arthritis in the United States". Centers for Disease Control and Prevention, US Department of Health and Human Services. 9 November 2016. На сайте: https://www.cdc.gov/ arthritis/data_statistics/arthritis-related-stats.htm
6. Pfuntner A, Wier LM, Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011: Statistical Brief #162. Source Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006-2013 Sep.
7. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 Epub 2014 Jan 24
8. Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.20 15.11.010 Epub 2015 Dec 2
9. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136 Epub 2016 Aug 19
10. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9
11. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2): CD002946.
12. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90.
13. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117.
14. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.
15. Moore R, Moore O, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9.
16. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. 2010;62(3):172-88.
17. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989;83:21-7.
18. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):731-8. Epub 2013 May 17
19. Karateev AE, Zhuravleva MV, Alekseev VV i dr. Effektivnost kombinacii lekarstvenny`x form ketoprofena lizinovoĭ soli (Artrozilen®) u pacientov s myshechno-skeletnoj bolyu v klinicheskoj praktike: Issledovanie KULON (Ketoprofen: udovletvorennost lecheniem i ocenka nezhelatelnyx yavleniĭ). Klinicheskaya farmakologiya i terapiya. 2013;22(4):22-30 (In Russ.).
20. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;(5):CD002947. doi: 10.1002/1 4651858.CD002947.pub2
21. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408.
22. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014 Feb;73(2):376-84. Epub 2013 Jan 23. doi: 10.1136/annrheumdis-2012-202485
23. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016;54(5):217-26. Epub 2016 Nov 28.
24. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1955-65. doi: 10.1016/j.joca.2015.05.016 Epub 2015 May 30.
25. Belluzzi E, El Hadi H, Granzotto M, et al. Systemic and Local Adipose Tissue in Knee Osteoarthritis. J Cell Physiol. 2017 Aug;232(8):1971-8. doi: 10.1002/jcp.25716 Epub 2017 Mar 3.
26. Nawai A, Leveille SG, Shmerling RH, et al. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017 Feb 21. doi: 10.1007/s40520-016-0700-9 [Epub ahead of print.]
27. Larsson C, Hansson EE, Sundquist K, Jakobsson U. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2016 Nov 25;1-9. doi: 10.1080/03009742.2016.1218543 [Epub ahead of print.]
28. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008 Sep 2;9:116. doi: 10.1186/1471-2474-9-116
29. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4
30. Chan WP, Huang GS, Hsu SM, et al. Radiographic joint space narrowing in osteoarthritis of the knee: relationship to meniscal tears and duration of pain. Skeletal Radiol. 2008 Oct;37(10):917-22. doi: 10.1007/s00256-008-0530-8 Epub 2008 Jul 2.
31. Murphy SL, Lyden AK, Phillips K, et al. Association between pain, radiographic severity, and centrally-mediated symptoms in women with knee osteoarthritis. Arthritis Care Res (Hoboken). 2011 Nov;63(11):1543-9. doi: 10.1002/acr.20583
32. Raman S, FitzGerald U, Murphy JM. Interplay of Inflammatory Mediators with Epigenetics and Cartilage Modifications in Osteoarthritis. Front Bioeng Biotechnol. 2018 Mar 14;6:22. doi: 10.3389/fbioe.2018.00022. eCollection 2018
33. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1825-34. doi: 10.1016/j.joca.2015.08.015
34. Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425.
35. Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One. 2018 Jan 12;13(1):e0191045. doi: 10.1371/journal.pone.01910 45.eCollection 2018
36. Snelling SJ, Bas S, Puskas GJ, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One. 2017 Apr 11;12(4):e0175109. doi:10.1371/journal.pone.0175109.eCollect ion 2017
37. Karateev AE, Lila AM, Pogozheva EYu, i dr. Effektivnost` meloksikama pri ostroj boli v spine: danny`e nablyudatel`nogo neintervencionnogo mnogocentrovogo issledovaniya. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2018;118(6):24-30 (In Russ.).
38.Karateev AE, Pogozheva EYu, Filatova ES, i dr. Rezul`taty` rossijskogo mnogocentrovogo issledovaniya NOTA (NPVP dlya Obezbolivaniya: Terapevticheskij Analiz). Therapeutic Archive. 2018;90(6):65-73 (In Russ.).
39. Rai MF, Brophy RH, Sandell LJ. Osteoarthritis following meniscus and ligament injury: insights from translational studies and animal models. Curr Opin Rheumatol. 2019 Jan;31(1):70-9. doi: 10.1097/BOR.0000000 000000566
40. Mattap SM, Aitken D, Wills K, et al. Patellar tendon enthesis abnormalities and their association with knee pain and structural abnormalities in older adults. Osteoarthritis Cartilage. 2019 Mar; 27(3):449-458. doi: 10.1016/j.joca.2018.11.009 [Epub 2018 Dec 5]
41. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И., Эрдес Ш.Ф., Филатова Е.Г. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-5 [Filatova ES, Turovskaya EF, Alekseeva LI, E`rdes ShF, Filatova EG. Analiz patogeneticheskix mexanizmov xronicheskoj sustavnoj boli u bolnyx revmatoidny`m artritom i osteoartrozom kolennyx sustavov. Nauchno-prakticheskaya revmatologiya. 2014;52(6):631-5 (In Russ.)]. https://doi.org/10.14412/1995-4484-2014-631-635
42. Petersen KK, Olesen AE, Simonsen O, Arendt-Nielsen L. Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis. Pain. 2018 Oct 26. doi: 10.1097/j.pain.0000000000001427 [Epub ahead of print.]
43. De Oliveira Silva D, Rathleff MS, Petersen K, et al. Manifestations of Pain Sensitization Across Different Painful Knee Disorders: A Systematic Review Including Meta-analysis and Metaregression. Pain Med. 2018 Nov 13. doi: 10.1093/pm/pny177 [Epub ahead of print.]
2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X Epub 2015 Aug 28
3. Балабанова Р.М., Эрдес Ш.Ф. Распространенность ревматических заболеваний в России в 2012–2013 гг. Научно-практическая ревматология. 2015;53(2):120-4 [Balabanova RM, Erdes ShF. Rasprostranennost` revmaticheskix zabolevaniĭ v Rossii v 2012–2013 gg. Nauchno-prakticheskaya revmatologiya. 2015;53(2):120-4 (In Russ.)].
4. Фоломеева O.M., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяциях взрослого населения России и США. Научно-практическая ревматология. 2008;46(4):4-13 [Folomeeva OM, Galushko EA, Erdes ShF. Rasprostranennost revmaticheskix zabolevaniĭ v populyaciyax vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008;46(4):4-13 (In Russ.)].
5. "Arthritis-Related Statistics: Prevalence of Arthritis in the United States". Centers for Disease Control and Prevention, US Department of Health and Human Services. 9 November 2016. На сайте: https://www.cdc.gov/ arthritis/data_statistics/arthritis-related-stats.htm
6. Pfuntner A, Wier LM, Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011: Statistical Brief #162. Source Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006-2013 Sep.
7. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 Epub 2014 Jan 24
8. Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.20 15.11.010 Epub 2015 Dec 2
9. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136 Epub 2016 Aug 19
10. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9
11. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2): CD002946.
12. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90.
13. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117.
14. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.
15. Moore R, Moore O, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9.
16. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. 2010;62(3):172-88.
17. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989;83:21-7.
18. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):731-8. Epub 2013 May 17
19. Каратеев А.Е., Журавлева М.В., Алексеев В.В. и др. Эффективность комбинации лекарственных форм кетопрофена лизиновой соли (Артрозилен®) у пациентов с мышечно-скелетной болью в клинической практике: Исследование КУЛОН (Кетопрофен: удовлетворенность лечением и оценка нежелательных явлений). Клиническая фармакология и терапия. 2013;22(4):22-30 [Karateev AE, Zhuravleva MV, Alekseev VV i dr. Effektivnost kombinacii lekarstvenny`x form ketoprofena lizinovoĭ soli (Artrozilen®) u pacientov s myshechno-skeletnoj bolyu v klinicheskoj praktike: Issledovanie KULON (Ketoprofen: udovletvorennost lecheniem i ocenka nezhelatelnyx yavleniĭ). Klinicheskaya farmakologiya i terapiya. 2013;22(4):22-30 (In Russ.)].
20. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;(5):CD002947. doi: 10.1002/1 4651858.CD002947.pub2
21. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408.
22. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014 Feb;73(2):376-84. Epub 2013 Jan 23. doi: 10.1136/annrheumdis-2012-202485
23. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016;54(5):217-26. Epub 2016 Nov 28.
24. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1955-65. doi: 10.1016/j.joca.2015.05.016 Epub 2015 May 30.
25. Belluzzi E, El Hadi H, Granzotto M, et al. Systemic and Local Adipose Tissue in Knee Osteoarthritis. J Cell Physiol. 2017 Aug;232(8):1971-8. doi: 10.1002/jcp.25716 Epub 2017 Mar 3.
26. Nawai A, Leveille SG, Shmerling RH, et al. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017 Feb 21. doi: 10.1007/s40520-016-0700-9 [Epub ahead of print.]
27. Larsson C, Hansson EE, Sundquist K, Jakobsson U. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2016 Nov 25;1-9. doi: 10.1080/03009742.2016.1218543 [Epub ahead of print.]
28. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008 Sep 2;9:116. doi: 10.1186/1471-2474-9-116
29. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4
30. Chan WP, Huang GS, Hsu SM, et al. Radiographic joint space narrowing in osteoarthritis of the knee: relationship to meniscal tears and duration of pain. Skeletal Radiol. 2008 Oct;37(10):917-22. doi: 10.1007/s00256-008-0530-8 Epub 2008 Jul 2.
31. Murphy SL, Lyden AK, Phillips K, et al. Association between pain, radiographic severity, and centrally-mediated symptoms in women with knee osteoarthritis. Arthritis Care Res (Hoboken). 2011 Nov;63(11):1543-9. doi: 10.1002/acr.20583
32. Raman S, FitzGerald U, Murphy JM. Interplay of Inflammatory Mediators with Epigenetics and Cartilage Modifications in Osteoarthritis. Front Bioeng Biotechnol. 2018 Mar 14;6:22. doi: 10.3389/fbioe.2018.00022. eCollection 2018
33. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1825-34. doi: 10.1016/j.joca.2015.08.015
34. Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425.
35. Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One. 2018 Jan 12;13(1):e0191045. doi: 10.1371/journal.pone.01910 45.eCollection 2018
36. Snelling SJ, Bas S, Puskas GJ, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One. 2017 Apr 11;12(4):e0175109. doi:10.1371/journal.pone.0175109.eCollect ion 2017
37. Каратеев А.Е., Лила А.М., Погожева Е.Ю. и др. Эффективность мелоксикама при острой боли в спине: данные наблюдательного неинтервенционного многоцентрового исследования. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(6):24-30 [Karateev AE, Lila AM, Pogozheva EYu, i dr. Effektivnost` meloksikama pri ostroj boli v spine: danny`e nablyudatel`nogo neintervencionnogo mnogocentrovogo issledovaniya. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2018;118(6):24-30 (In Russ.)].
38. Каратеев А.Е., Погожева Е.Ю., Филатова Е.С., и др. Результаты российского многоцентрового исследования НОТА (НПВП для Обезболивания: Терапевтический Анализ). Терапевтический архив. 2018;90(6):65-73 [Karateev AE, Pogozheva EYu, Filatova ES, i dr. Rezul`taty` rossijskogo mnogocentrovogo issledovaniya NOTA (NPVP dlya Obezbolivaniya: Terapevticheskij Analiz). Therapeutic Archive. 2018;90(6):65-73 (In Russ.)].
39. Rai MF, Brophy RH, Sandell LJ. Osteoarthritis following meniscus and ligament injury: insights from translational studies and animal models. Curr Opin Rheumatol. 2019 Jan;31(1):70-9. doi: 10.1097/BOR.0000000 000000566
40. Mattap SM, Aitken D, Wills K, et al. Patellar tendon enthesis abnormalities and their association with knee pain and structural abnormalities in older adults. Osteoarthritis Cartilage. 2019 Mar; 27(3):449-458. doi: 10.1016/j.joca.2018.11.009 [Epub 2018 Dec 5]
41. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И., Эрдес Ш.Ф., Филатова Е.Г. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-5 [Filatova ES, Turovskaya EF, Alekseeva LI, E`rdes ShF, Filatova EG. Analiz patogeneticheskix mexanizmov xronicheskoj sustavnoj boli u bolnyx revmatoidny`m artritom i osteoartrozom kolennyx sustavov. Nauchno-prakticheskaya revmatologiya. 2014;52(6):631-5 (In Russ.)]. https://doi.org/10.14412/1995-4484-2014-631-635
42. Petersen KK, Olesen AE, Simonsen O, Arendt-Nielsen L. Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis. Pain. 2018 Oct 26. doi: 10.1097/j.pain.0000000000001427 [Epub ahead of print.]
43. De Oliveira Silva D, Rathleff MS, Petersen K, et al. Manifestations of Pain Sensitization Across Different Painful Knee Disorders: A Systematic Review Including Meta-analysis and Metaregression. Pain Med. 2018 Nov 13. doi: 10.1093/pm/pny177 [Epub ahead of print.]
________________________________________________
2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X Epub 2015 Aug 28
3. Balabanova RM, Erdes ShF. Rasprostranennost` revmaticheskix zabolevaniĭ v Rossii v 2012–2013 gg. Nauchno-prakticheskaya revmatologiya. 2015;53(2):120-4 (In Russ.).
4. Folomeeva OM, Galushko EA, Erdes ShF. Rasprostranennost revmaticheskix zabolevaniĭ v populyaciyax vzroslogo naseleniya Rossii i SShA. Nauchno-prakticheskaya revmatologiya. 2008;46(4):4-13 (In Russ.).
5. "Arthritis-Related Statistics: Prevalence of Arthritis in the United States". Centers for Disease Control and Prevention, US Department of Health and Human Services. 9 November 2016. На сайте: https://www.cdc.gov/ arthritis/data_statistics/arthritis-related-stats.htm
6. Pfuntner A, Wier LM, Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011: Statistical Brief #162. Source Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006-2013 Sep.
7. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003 Epub 2014 Jan 24
8. Bruyère O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis-From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi:10.1016/j.semarthrit.20 15.11.010 Epub 2015 Dec 2
9. Robinson WH, Lepus CM, Wang Q, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016 Oct;12(10):580-92. doi: 10.1038/nrrheum.2016.136 Epub 2016 Aug 19
10. Mathiessen A, Conaghan PG. Synovitis in osteoarthritis: current understanding with therapeutic implications. Arthritis Res Ther. 2017 Feb 2;19(1):18. doi: 10.1186/s13075-017-1229-9
11. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2): CD002946.
12. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90.
13. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117.
14. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808.
15. Moore R, Moore O, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69:374-9.
16. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo. 2010;62(3):172-88.
17. Le Loet X. Safety of ketoprofen in the elderly: a prospective study on 20,000 patients. Scand J Rheumatol Suppl. 1989;83:21-7.
18. Sarzi-Puttini P, Atzeni F, Lanata L, Bagnasco M. Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. Clin Exp Rheumatol. 2013 Sep-Oct;31(5):731-8. Epub 2013 May 17
19. Karateev AE, Zhuravleva MV, Alekseev VV i dr. Effektivnost kombinacii lekarstvenny`x form ketoprofena lizinovoĭ soli (Artrozilen®) u pacientov s myshechno-skeletnoj bolyu v klinicheskoj praktike: Issledovanie KULON (Ketoprofen: udovletvorennost lecheniem i ocenka nezhelatelnyx yavleniĭ). Klinicheskaya farmakologiya i terapiya. 2013;22(4):22-30 (In Russ.).
20. Cameron M, Chrubasik S. Oral herbal therapies for treating osteoarthritis. Cochrane Database Syst Rev. 2014 May 22;(5):CD002947. doi: 10.1002/1 4651858.CD002947.pub2
21. Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408.
22. Maheu E, Cadet C, Marty M, et al. Randomised, controlled trial of avocado-soybean unsaponifiable (Piascledine) effect on structure modification in hip osteoarthritis: the ERADIAS study. Ann Rheum Dis. 2014 Feb;73(2):376-84. Epub 2013 Jan 23. doi: 10.1136/annrheumdis-2012-202485
23. Głuszko P, Stasiek M. Symptom-modifying effects of oral avocado/soybean unsaponifiables in routine treatment of knee osteoarthritis in Poland. An open, prospective observational study of patients adherent to a 6-month treatment. Reumatologia. 2016;54(5):217-26. Epub 2016 Nov 28.
24. Courties A, Gualillo O, Berenbaum F, Sellam J. Metabolic stress-induced joint inflammation and osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1955-65. doi: 10.1016/j.joca.2015.05.016 Epub 2015 May 30.
25. Belluzzi E, El Hadi H, Granzotto M, et al. Systemic and Local Adipose Tissue in Knee Osteoarthritis. J Cell Physiol. 2017 Aug;232(8):1971-8. doi: 10.1002/jcp.25716 Epub 2017 Mar 3.
26. Nawai A, Leveille SG, Shmerling RH, et al. Pain severity and pharmacologic pain management among community-living older adults: the MOBILIZE Boston study. Aging Clin Exp Res. 2017 Feb 21. doi: 10.1007/s40520-016-0700-9 [Epub ahead of print.]
27. Larsson C, Hansson EE, Sundquist K, Jakobsson U. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2016 Nov 25;1-9. doi: 10.1080/03009742.2016.1218543 [Epub ahead of print.]
28. Bedson J, Croft PR. The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature. BMC Musculoskelet Disord. 2008 Sep 2;9:116. doi: 10.1186/1471-2474-9-116
29. Wang Y, Teichtahl AJ, Abram F, et al. Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. Arthritis Res Ther. 2018 Nov 6;20(1):250. doi: 10.1186/s13075-018-1751-4
30. Chan WP, Huang GS, Hsu SM, et al. Radiographic joint space narrowing in osteoarthritis of the knee: relationship to meniscal tears and duration of pain. Skeletal Radiol. 2008 Oct;37(10):917-22. doi: 10.1007/s00256-008-0530-8 Epub 2008 Jul 2.
31. Murphy SL, Lyden AK, Phillips K, et al. Association between pain, radiographic severity, and centrally-mediated symptoms in women with knee osteoarthritis. Arthritis Care Res (Hoboken). 2011 Nov;63(11):1543-9. doi: 10.1002/acr.20583
32. Raman S, FitzGerald U, Murphy JM. Interplay of Inflammatory Mediators with Epigenetics and Cartilage Modifications in Osteoarthritis. Front Bioeng Biotechnol. 2018 Mar 14;6:22. doi: 10.3389/fbioe.2018.00022. eCollection 2018
33. Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015 Nov;23(11):1825-34. doi: 10.1016/j.joca.2015.08.015
34. Dell'Isola A, Allan R, Smith SL, et al. Identification of clinical phenotypes in knee osteoarthritis: a systematic review of the literature. BMC Musculoskelet Disord. 2016 Oct 12;17(1):425.
35. Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One. 2018 Jan 12;13(1):e0191045. doi: 10.1371/journal.pone.01910 45.eCollection 2018
36. Snelling SJ, Bas S, Puskas GJ, et al. Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS One. 2017 Apr 11;12(4):e0175109. doi:10.1371/journal.pone.0175109.eCollect ion 2017
37. Karateev AE, Lila AM, Pogozheva EYu, i dr. Effektivnost` meloksikama pri ostroj boli v spine: danny`e nablyudatel`nogo neintervencionnogo mnogocentrovogo issledovaniya. Zhurnal nevrologii i psixiatrii im. S.S. Korsakova. 2018;118(6):24-30 (In Russ.).
38.Karateev AE, Pogozheva EYu, Filatova ES, i dr. Rezul`taty` rossijskogo mnogocentrovogo issledovaniya NOTA (NPVP dlya Obezbolivaniya: Terapevticheskij Analiz). Therapeutic Archive. 2018;90(6):65-73 (In Russ.).
39. Rai MF, Brophy RH, Sandell LJ. Osteoarthritis following meniscus and ligament injury: insights from translational studies and animal models. Curr Opin Rheumatol. 2019 Jan;31(1):70-9. doi: 10.1097/BOR.0000000 000000566
40. Mattap SM, Aitken D, Wills K, et al. Patellar tendon enthesis abnormalities and their association with knee pain and structural abnormalities in older adults. Osteoarthritis Cartilage. 2019 Mar; 27(3):449-458. doi: 10.1016/j.joca.2018.11.009 [Epub 2018 Dec 5]
41. Филатова Е.С., Туровская Е.Ф., Алексеева Л.И., Эрдес Ш.Ф., Филатова Е.Г. Анализ патогенетических механизмов хронической суставной боли у больных ревматоидным артритом и остеоартрозом коленных суставов. Научно-практическая ревматология. 2014;52(6):631-5 [Filatova ES, Turovskaya EF, Alekseeva LI, E`rdes ShF, Filatova EG. Analiz patogeneticheskix mexanizmov xronicheskoj sustavnoj boli u bolnyx revmatoidny`m artritom i osteoartrozom kolennyx sustavov. Nauchno-prakticheskaya revmatologiya. 2014;52(6):631-5 (In Russ.)]. https://doi.org/10.14412/1995-4484-2014-631-635
42. Petersen KK, Olesen AE, Simonsen O, Arendt-Nielsen L. Mechanistic pain profiling as a tool to predict the efficacy of 3-week nonsteroidal anti-inflammatory drugs plus paracetamol in patients with painful knee osteoarthritis. Pain. 2018 Oct 26. doi: 10.1097/j.pain.0000000000001427 [Epub ahead of print.]
43. De Oliveira Silva D, Rathleff MS, Petersen K, et al. Manifestations of Pain Sensitization Across Different Painful Knee Disorders: A Systematic Review Including Meta-analysis and Metaregression. Pain Med. 2018 Nov 13. doi: 10.1093/pm/pny177 [Epub ahead of print.]
Авторы
А.Е. Каратеев, А.М. Лила, Е.Ю. Погожева, В.Н. Амирджанова, Е.С. Филатова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
V.A. Nasonova Scientific and Research Institute of Rheumatology, Moscow, Russia
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», Москва, Россия
________________________________________________
V.A. Nasonova Scientific and Research Institute of Rheumatology, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.